IGFBP-L1 Antibody [Unconjugated]

IGFBP‑L1 was detected in immersion fixed paraffin-embedded sections of mouse embryo brain using Goat Anti-Mouse IGFBP‑L1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4130) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Mu
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IGFBP-L1 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse IGFBP-L1
  Leu18-Leu270
  Accession # Q80W15
• Specificity: Detects mouse IGFBP-L1 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross‑reactivity with recombinant human IGFBP-L1 is observed and less than 1% cross-reactivity with recombinant mouse IGFBP-7 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IGFBPL1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-L1 Antibody [Unconjugated]

• bA113O24.1
• IGFBPL1 insulin-like growth factor binding protein-like 1
• IGFBPL1
• IGFBP-L1
• IGFBP-RP4

Background

Insulin-like Growth Factor Binding Protein-Like 1 (IGFBP‑L1), also known as IGFBP-rP4, is a 38 kDa secreted member of the IGFBP superfamily of proteins. IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins (1). IGFBP-L1 contains an N-terminal IGFBP motif, a Kazal-type serine protease inhibitor region, and a C‑terminal Ig-like domain (2, 3). Mature mouse IGFBP-L1 shares 76% and 96% amino acid (aa) sequence identity with human and rat IGFBP-L1, respectively. It shares 38%-41% aa sequence identity with mouse IGFBP-7 and IGFBP-rp10 and 20%‑24% aa sequence identity with mouse IGFBP-1, -2, -3, -4, -5, and -6. IGFBP-L1 is most highly expressed in testis and brain, while lower levels are more broadly expressed (3). IGFBP-L1 is expressed in regionally and temporally distinct patterns during forebrain development (4). IGFBP-L1 inhibits cell proliferation in vitro and is downregulated in many colon and lung tumors (3). Transcriptional downregulation by promoter methylation is predictive of breast cancer aggressiveness (5).

1. Firth, S.M. and R.C. Baxter (2002) Endocr. Rev. 23:824.
2. Accession # Q80W15.
3. Cai, Z. et al. (2005) Biochem. Biophys. Res. Commun. 331:261.
4. Gonda, Y. et al. (2007) Gene Expr. Patterns 7:431.
5. Smith, P. et al. (2007) Clin. Cancer Res. 13:4061.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGFBP-L1 Antibody (AF4130)(3)

Publications using AF4130

• Pan, L;Cho, KS;Wei, X;Xu, F;Lennikov, A;Hu, G;Tang, J;Guo, S;Chen, J;Kriukov, E;Kyle, R;Elzaridi, F;Jiang, S;Dromel, PA;Young, M;Baranov, P;Do, CW;Williams, RW;Chen, J;Lu, L;Chen, DF; IGFBPL1 is a master driver of microglia homeostasis and resolution of neuroinflammation in glaucoma and brain tauopathy Cell reports 2023-07-31 [PMID: 37527036] (IHC, Mouse)
• E Butti, S Cattaneo, M Bacigalupp, M Cambiaghi, GM Scotti, E Brambilla, F Ruffini, G Sferruzza, M Ripamonti, F Simeoni, L Cacciaguer, A Zanghì, A Quattrini, R Fesce, P Panina-Bor, F Giannese, D Cittaro, T Kuhlmann, P D'Adamo, MA Rocca, S Taverna, G Martino Neural precursor cells tune striatal connectivity through the release of IGFBPL1 Nature Communications, 2022-12-08;13(1):7579. 2022-12-08 [PMID: 36482070] (Immunohistochemistry, Mouse)
• C Guo, KS Cho, Y Li, K Tchedre, C Antolik, J Ma, J Chew, TP Utheim, XA Huang, H Yu, MTA Malik, N Anzak, DF Chen IGFBPL1 Regulates Axon Growth through IGF-1-mediated Signaling Cascades Sci Rep, 2018-02-01;8(1):2054. 2018-02-01 [PMID: 29391597] (IHC, Mouse)

Bioinformatics

• Gene Symbol: IGFBPL1
• Uniprot:
  • Q80W15()